Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Structure
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) structure
CAS No.
2151854-33-8
Chemical Name:
Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)
Synonyms
MPT0G211 mesylate;Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1)
CBNumber:
CB710974040
Molecular Formula:
C18H19N3O5S
Molecular Weight:
389.43
MDL Number:
MOL File:
2151854-33-8.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-04-21 10:31:43
Request For Quotation

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Chemical Properties,Uses,Production

Uses

MPT0G211 mesylate is a potent, orally active and selective HDAC6 inhibitor (IC50=0.291 nM). MPT0G211 mesylate displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 mesylate can penetrate the blood-brain barrier. MPT0G211 mesylate ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 mesylate has anti-metastatic and neuroprotective effects. Anticancer activities[1][2][3].

in vivo

MPT0G211 mesylate (50 mg/kg; p.o.; daily for 3 months) significantly ameliorates the spatial memory impairment[1].
MPT0G211 mesylate (25 mg/kg; i.p.; qd; day 73 post-tumor injection) reduces numbers of nodules and lung weights[2].
MPT0G211 mesylate treatment not only diminishes tau phosphorylation by inhibition GSK3β activity but also enhances the acetylation of Hsp90, which causes the downregulation of HDAC6/Hsp90 binding and facilitates proteasomal degradation of polyubiquitinated p-tau[1].

Animal Model:Triple transgenic (3×Tg-AD) mice (harboring APPSwe and tauP301L mutant transgenes[1]
Dosage:50mg/kg
Administration:P.o.; daily for 3 months
Result:Significantly ameliorated the spatial memory impairment.
Animal Model:Female SCID mice (bearing MDA-MB-231 cells)[2]
Dosage:25mg/kg
Administration:I.p.; qd; day 73 post-tumor injection
Result:Significantly reduced numbers of nodules and lung weights.

IC 50

HDAC6: 0.291 μM (IC50)

References

[1] Fan SJ, et al. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death Dis. 2018;9(6):655. Published 2018 May 29. DOI:10.1038/s41419-018-0688-5
[2] Hsieh YL, et al. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochim Biophys Acta Mol Cell Res. 2019;1866(6):992-1003. DOI:10.1016/j.bbamcr.2019.03.003
[3] Tu HJ, et al. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells. Clin Epigenetics. 2018;10(1):162. Published 2018 Dec 29. DOI:10.1016/j.bbamcr.2019.03.003

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Preparation Products And Raw materials

Raw materials

Preparation Products

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) Suppliers

Global( 3)Suppliers
Supplier Tel Email Country ProdList Advantage
BOC Sciences 1-631-485-4226; 16314854226 info@bocsci.com United States 9920 65
TargetMol Chemicals Inc. 15002134094 marketing@targetmol.cn China 29874 58
TargetMol Chemicals Inc. 13564774135 marketing@targetmol.com United States 19950 58
Supplier Advantage
BOC Sciences 65
TargetMol Chemicals Inc. 58
TargetMol Chemicals Inc. 58

View Lastest Price from Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
MPT0G211 mesylate pictures 2026-04-20 MPT0G211 mesylate
2151854-33-8
 $1520.00-2500.00 10g TargetMol Chemicals Inc.

2151854-33-8(Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1))Related Search:

Carbamazepine N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Tucidinostat (Chidamide) LMK-235 4-Phenylbutyric acid
Entinostat

1of2

Benzamide, N-hydroxy-4-[(8-quinolinylamino)methyl]-, compd. with methanesulfonate (1:1) MPT0G211 mesylate 2151854-33-8